Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jul 11;73(8):1400-1402.
doi: 10.1136/gutjnl-2023-331115.

FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials

Alessandro Mantovani  1 , Herbert Tilg  2 , Giovanni Targher  3   4
Affiliations
Comment

FGF-21 analogues for treatment of non-alcoholic steatohepatitis and fibrosis: a meta-analysis with fragility index of phase 2 randomised placebo-controlled trials

Alessandro Mantovani et al. Gut. .
No abstract available

Keywords: LIVER BIOPSY; META-ANALYSIS; NONALCOHOLIC STEATOHEPATITIS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: HT is an associate editor of the journal and GT is an editorial board member of the journal.

Figures

Figure 1
Figure 1
Forest plots and pooled estimates of the effects of long-acting FGF-21 analogues on the histological resolution of NASH with no worsening of fibrosis ((A), n=3 RCTs6–8) or the improvement in fibrosis of one stage or more without worsening of NASH ((B), n=5 RCTs4–8) compared with placebo. The pooled and individual effect sizes for all RCTs are expressed as OR and 95% CIs, as estimated by both common-effects and random-effects models. For the active-comparator group (ie, participants using FGF-21 analogues), we calculated the individual effect sizes of each RCT by combining the treatment effect data of variable dosages of FGF-21 analogues into a single group (to avoid including individuals in the placebo group several times in the analysis). With regard to this, it is important to note that before combining the data of the active-comparator group for each RCT, we have previously tested in a multivariate meta-regression analysis that neither the different type nor the different dosage of FGF-21 analogue used in each RCT were significant predictors of the observed effects of this drug class on the histological liver endpoints. FGF-21, fibroblast growth factor-21; NASH, non-alcoholic steatohepatitis; RCT, non-alcoholic steatohepatitis.
See this image and copyright information in PMC

Comment on

References

    1. Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194–209. 10.1136/gutjnl-2021-324305 - DOI - PMC - PubMed
    1. Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol 2020;16:654–67. 10.1038/s41574-020-0386-0 - DOI - PubMed
    1. Atal I, Porcher R, Boutron I, et al. . The statistical significance of meta-analyses is frequently fragile: definition of a fragility index for meta-analyses. J Clin Epidemiol 2019;111:32–40. 10.1016/j.jclinepi.2019.03.012 - DOI - PubMed
    1. Harrison SA, Ruane PJ, Freilich BL, et al. . Efruxifermin in non-alcoholic Steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2A trial. Nat Med 2021;27:1262–71. 10.1038/s41591-021-01425-3 - DOI - PubMed
    1. Harrison SA, Ruane PJ, Freilich B, et al. . A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. JHEP Rep 2023;5:100563. 10.1016/j.jhepr.2022.100563 - DOI - PMC - PubMed

MeSH terms

Substances